Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Indole+1 more
Cannabinoid receptor agonistTHC, JWH-018, JWH-250 +1 moreTHC, JWH-018, JWH-250, cannabinoids (all CB1 agonists) show less
JWH-073
JWH-073 is a synthetic cannabinoid of the naphthoylindole class. It is the N-butyl homolog of JWH-018 — roughly half as potent but still substantially stronger than cannabis.[1] It activates cannabinoid receptors in the brain as a full agonist, with no ceiling on how strong the effect can get.[2]
JWH-073 ((1-butylindol-3-yl)-naphthalen-1-ylmethanone) is a synthetic cannabinoid of the naphthoylindole class. It is the N-butyl homolog of JWH-018, roughly half as potent but still substantially stronger than Δ9-THC.[1] JWH-073 is a full agonist at CB1 and CB2 cannabinoid receptors, producing its effects by overriding the brain's endocannabinoid signaling system without the ceiling that limits cannabis.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Indole+1 more
Cannabinoid receptor agonistTHC, JWH-018, JWH-250 +1 moreTHC, JWH-018, JWH-250, cannabinoids (all CB1 agonists) show less
JWH-073 was synthesized by John W. Huffman around 1984 as one of over 400 cannabinoid research tools.[3] In early 2009 it replaced JWH-018 in "Spice" and "K2" blends after Germany banned JWH-018[4] — starting the cat-and-mouse reformulation pattern that defined the synthetic cannabinoid market. It is now permanently controlled in the United States and most Western countries.[5]
Subjective effects include euphoria, sedation, appetite enhancement, and pain suppression. The experience resembles cannabis compressed into a shorter window — low doses bring deep relaxation, but a narrow margin separates comfort from adverse territory, with anxiety and disorientation arriving quickly as the dose rises.[6] Rapid heartbeat, anxiety, paranoia, and at higher doses seizures or acute psychosis are documented.[7]
JWH-073 produces physical and psychological dependence, and its toxicity profile is steeper than cannabis.[8][9] Full agonism means no ceiling — effects can escalate to seizures, heart emergencies, and multi-organ failure without the natural limit that Δ9-THC provides.[9] No controlled human study exists; all knowledge comes from animal models, case reports, and laboratory pharmacology.[10]
History[edit]
Discovery
John William Huffman synthesized JWH-073 at Clemson University around 1984 as part of a NIDA-funded project.[3] His laboratory produced over 400 cannabinoid compounds as research tools for mapping the endocannabinoid system. JWH-073 appeared in published structure-activity studies on naphthoylindoles[11][12] and was never intended for human use.
Market emergence
JWH-073 appeared in "Spice" and "K2" herbal blends in February 2009, substituted for JWH-018 after Germany banned that compound in late 2008.[4] This rapid substitution — one compound banned, another taking its place — defined the synthetic cannabinoid market for years.
Prohibition
The UK banned JWH-073 under a generic naphthoylindole definition around December 2009.[13] The US DEA temporarily scheduled it in March 2011 as an "imminent hazard to public safety",[14] then permanently in March 2012.[5] Australia and Canada followed in 2011.[13]
The "JWH" naming convention — a chemist's initials followed by a lab index number — became synonymous with the synthetic cannabinoid wave of the late 2000s and early 2010s. Huffman publicly called the recreational use of his research tools "a disaster." JWH-073's identity is inseparable from the "Spice" phenomenon: a period when dozens of research chemicals cycled through herbal blend products faster than regulators could schedule them.
Chemistry[edit]
Structure
JWH-073 belongs to the naphthoylindole class of synthetic cannabinoids.[15] The molecule connects an indole ring — carrying a four-carbon butyl chain — to a naphthalene ring through a carbonyl bridge, the structural feature responsible for binding to cannabinoid receptors.[16] Its molecular formula is C₂₃H₂₁NO (327.4 g/mol).
The four-carbon chain is one carbon shorter than the five-carbon chain in JWH-018. That single difference is why JWH-073 binds cannabinoid receptors roughly half as strongly.[11][12][16] JWH-073 has no stereocenters and exists as one molecular form.[15]
Pharmacology[edit]
Mechanism of action
JWH-073 is a full agonist at CB1 and CB2 cannabinoid receptors.[2][17] Unlike Δ9-THC — a partial agonist with a built-in ceiling — JWH-073 drives receptors to maximum activation. There is no natural stopping point.
CB1 activation triggers dopamine release in the brain's mesolimbic pathway, producing euphoria and reinforcing repeated use.[17] JWH-073 also suppresses memory formation in the hippocampus by roughly 60% in laboratory settings.[18]
Pharmacokinetics
When smoked, onset is rapid. The body converts JWH-073 into metabolites through hydroxylation[2][19] — one partially blocks the parent compound's effects as it builds up,[2] another retains full activity.[2] A urinary marker is detectable 11–25 days after stopping,[20] and standard cannabis drug screens will not detect it.[21]
Neuroscience[edit]
Where it acts
JWH-073 activates CB1 receptors concentrated in the hippocampus, neocortex, basal ganglia, and cerebellum. Normally, the brain's own cannabinoid molecules are released on demand to fine-tune specific synapses. JWH-073 floods these receptors indiscriminately — suppressing memory circuits, stimulating reward circuits, and broadly disrupting cortical activity.[18][17]
Why it matters
The endocannabinoid system acts as a thermostat for synaptic signaling. JWH-073 overrides that thermostat, activating receptors to maximum regardless of what any circuit needs.[17] This explains the dose response: gentle sedation at lower exposures, agitation, seizures, and psychosis when receptors are saturated.
In mice, JWH-073 disrupts brain wave activity across multiple frequency bands for at least 24 hours after behavioral effects have cleared.[18] Whether this persists longer or accumulates with repeated use is unknown. No human neuroimaging studies have been conducted; the neural correlates of its subjective effects are entirely inferred from animal work. Whether the neutral-antagonist metabolite M4[2] contributes to the rapid subjective offset also remains untested.
Subjective Effects[edit]
JWH-073 produces a cannabis-like experience compressed into a shorter window. At lower amounts, the dominant feeling is warm sedation — relaxation, appetite stimulation, and mild euphoria. As the dose rises, effects push past the ceiling cannabis imposes, and relaxation gives way to anxiety and disorientation with little warning.
Compared to JWH-018, JWH-073 is roughly half as potent and reportedly shorter-acting. Compared to Δ9-THC, it shares the same broad character — altered time perception, euphoria, and appetite enhancement — but with a narrower gap between comfortable and adverse. The absence of CBD removes a factor that may moderate cannabis psychosis risk.
JWH-073 was synthesized by John W. Huffman at Clemson University as one of over 400 cannabinoid research tools developed under NIDA funding beginning in 1984.[3] It entered recreational markets in early 2009 as a replacement ingredient in "Spice" and "K2" herbal blends after JWH-018 was banned in Germany.[4] JWH-073 was permanently placed in Schedule I in the United States in March 2012 and is now controlled in most Western jurisdictions.[5]
Subjective effects include euphoria, sedation, appetite enhancement, and pain suppression. The experience resembles a compressed, steeper version of cannabis — deeper relaxation at intended doses but a much shorter margin before adverse territory.[6] Tachycardia, anxiety, paranoia, seizures, and acute psychosis are documented at higher doses or in vulnerable individuals.[7]
Tolerance develops through CB1 receptor desensitization, and physical and psychological dependence are documented at moderate severity.[8] Full agonist status gives JWH-073 a steeper toxicity gradient than cannabis — case reports document seizures, cardiovascular emergencies, and multi-organ dysfunction, with no established lethal dose.[9] No controlled human study has been published; the current understanding rests entirely on animal data, case reports, and in vitro pharmacology.[10]
History[edit]
Discovery
JWH-073 was created by John William Huffman — the compound's "JWH" prefix comes from his initials — at Clemson University, South Carolina.[3] Beginning around 1984, Huffman's NIDA-funded laboratory synthesized over 400 cannabinoid compounds as research tools for mapping the endocannabinoid system.[3] JWH-073 was published as part of broader structure-activity studies on naphthoylindoles[11][12] and was never intended for human consumption.
Market emergence
JWH-073 appeared in herbal smoking blends marketed as "Spice" and "K2" in February 2009, after Germany scheduled JWH-018 and related compounds in December 2008.[4] Manufacturers rapidly substituted JWH-073 into products to circumvent the new bans — a pattern of cat-and-mouse reformulation that would define the synthetic cannabinoid market for years. Austria formally notified the EMCDDA of JWH-073 in a branded product called "Topaz" in July 2010.
Prohibition
Regulatory responses came quickly across multiple jurisdictions. The United Kingdom banned JWH-073 under a generic naphthoylindole definition around December 2009.[13] The US DEA temporarily placed it in Schedule I in March 2011 as an "imminent hazard to public safety",[14] with permanent scheduling following in March 2012.[5] Australia and Canada prohibited JWH-073 in 2011.[13]
The "JWH" naming convention — initials of the synthesizing chemist followed by a laboratory index number — became synonymous with the synthetic cannabinoid wave of the late 2000s and early 2010s. Huffman himself publicly expressed dismay that his research tools were being consumed recreationally, calling the situation "a disaster." The compound's identity is inseparable from the broader "Spice" phenomenon: a period in which dozens of research chemicals cycled through herbal blend products faster than regulators could schedule them.
Chemistry[edit]
Structure
JWH-073 belongs to the naphthoylindole class of synthetic cannabinoids. The molecule consists of three connected elements: an indole ring bearing an N-butyl chain (four carbons), a naphthalene ring system, and a carbonyl bridge linking the two at the indole C-3 position.[15] This carbonyl bridge is the primary pharmacophore — the structural feature responsible for anchoring the molecule in the CB1 binding pocket.[16]
| Molecular formula | C₂₃H₂₁NO |
| Molecular weight | 327.4 g/mol |
Structure-activity relationships
Within the naphthoylindole series, the length of the N-alkyl chain on the indole nitrogen is the primary determinant of CB1 binding strength.[11][12] JWH-073's four-carbon (butyl) chain is one methylene unit shorter than the five-carbon (pentyl) chain of JWH-018. Computational modeling confirms that this single-carbon difference predicts lower CB1 affinity, explaining why JWH-073 is roughly half as potent as JWH-018 in vivo.[16]
Stereochemistry
JWH-073 has no stereocenters and exists as a single achiral molecular species.[15] Enantiomeric considerations do not apply.
Physical properties
No published melting point, solubility, or stability data have been identified. As a naphthoylindole, the compound is expected to be lipophilic and poorly water-soluble, but substance-specific characterization has not been reported.
Pharmacology[edit]
Mechanism of action
JWH-073 is a full agonist at both CB1 and CB2 cannabinoid receptors.[2][17] This means it drives maximal receptor activation — equivalent to the reference compound CP-55,940 in laboratory assays[2] — unlike Δ9-THC, which is a partial agonist with a built-in ceiling on how strongly it can stimulate CB1.
When JWH-073 binds CB1, it triggers a cascade of downstream effects: reduced intracellular signaling molecules,[18] changes in ion channel activity at nerve terminals, and dose-dependent release of dopamine in the brain's mesolimbic pathway.[17] This dopamine release — fully blocked by the CB1 antagonist AM251 — underlies the compound's reinforcing and euphoria-producing properties.
JWH-073 also suppresses a key memory process called long-term potentiation in the hippocampus by roughly 60% in laboratory settings.[19] This suppression is the direct mechanism behind the short-term memory suppression characteristic of cannabinoid intoxication.
Pharmacokinetics
No controlled human pharmacokinetic study has been published for JWH-073. A validated method for controlled smoked administration exists, but results remain unpublished.[10]
When smoked, onset is rapid — consistent with inhaled cannabinoid pharmacology. The parent compound is quickly cleared from blood, with detection beyond 24 hours uncommon.inferred The body extensively metabolizes JWH-073 through hydroxylation, producing several metabolites with varying activity.[2][18] One metabolite (M4) acts as a neutral antagonist at CB1 — it may partially oppose the parent compound's effects as metabolism proceeds.[2] Another metabolite (M5) retains full activity at both CB1 and CB2.[2]
The primary urinary marker (JWH-073-COOH) is detectable for 11–25 days after cessation, with a creatinine-normalized half-life of 9.3 days.[20] Standard cannabis urine drug screens do not detect JWH-073 or its metabolites; specialized laboratory methods are required.[21]
Neuroscience[edit]
Where it acts
JWH-073 directly activates CB1 receptors, which are concentrated in the hippocampus, neocortex, basal ganglia, and cerebellum. Endocannabinoids normally act as precision retrograde signals — released on demand to fine-tune neurotransmitter release at specific synapses. JWH-073 bypasses this demand-driven system, flooding CB1 receptors indiscriminately regardless of local circuit needs. The result is widespread disruption of synaptic balance: memory circuits in the hippocampus are suppressed (producing the characteristic short-term amnesia), reward circuits in the nucleus accumbens are stimulated (producing euphoria), and cortical activity is broadly altered.[19][17]
Why it matters
The most explanatory framework is endocannabinoid tone disruption. The endocannabinoid system functions as a homeostatic thermostat for synaptic transmission. Full exogenous agonists like JWH-073 override this thermostat, producing maximal receptor activation independent of what any given circuit actually needs. This indiscriminate override explains the bidirectional dose-response: gentle sedation and anxiolysis at lower CB1 engagement, transitioning to agitation, seizures, and psychosis when receptors are saturated. The dose-dependent dopamine release in the mesolimbic pathway[17] maps onto the "wanting" component of reward that drives compulsive use.
EEG recordings in mice show that JWH-073 suppresses brain wave activity across multiple frequency bands, with disruption persisting at 24 hours even after behavioral effects have resolved.[19] Whether this subclinical disruption extends further, or accumulates with repeated dosing, is unknown.
Subjective Effects[edit]
JWH-073 produces a cannabis-like experience compressed into a shorter window and steepened in dose-response. At lower exposures the compound delivers warm sedation, mild euphoria, and appetite stimulation; as dose increases, the full agonist pharmacology pushes effects past the ceiling that cannabis imposes — deeper relaxation gives way to anxiety, paranoia, and disorientation with little warning. Individual responses are highly variable, and the unpredictable composition of herbal blend products adds a layer of dose uncertainty absent from most substance classes. Set, setting, and psychiatric history substantially shape outcome.
Compared to JWH-018, JWH-073 is roughly half as potent and reportedly shorter-acting, though no controlled head-to-head comparison exists. Compared to Δ9-THC, the experience shares the same receptor-mediated character — euphoria, altered time perception, appetite enhancement — but the full agonist ceiling and absence of CBD produce a narrower window between a comfortable experience and an adverse one.
Effect Grid
Clear cannabis-like euphoria and sedation dominate. Appetite enhancement is pronounced, pain suppression becomes noticeable, and time alteration produces a subjective slowing of temporal perception. Emotional enhancement colors the experience — music, food, and social interaction may feel more engaging.
Physical effects are evident: bodily heaviness, motor control impairment, dry mouth, and dehydration sensation. Heart rate elevation is common. Cognitive function is reduced — thought deceleration, analysis suppression, and mild memory impairment are typical. Some users experience anxiety or paranoia at this level, particularly in unfamiliar settings.
Total duration is approximately 1–2 hours. Functional impairment is significant enough to preclude driving or complex tasks. Product variability in herbal blends makes consistent dosing at this tier unreliable.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Taste enhancement · Color enhancement · Auditory enhancement · Depth perception distortion · Visual haze / noise · Geometry
Depth perception distortion · Visual haze / noise · Geometry
Dehydration sensation · Bodily heaviness · Abnormal heartbeat · Dizziness · Heart rate perception changes · Physical fatigue · Appetite enhancement · Spontaneous body sensations · Pain suppression · Muscle relaxation · Tactile euphoria · Headache · Laughter fits · Pupil dilation · Insomnia · Nausea · Restlessness · Trembling · Vomiting
Heart rate perception changes · Physical fatigue · Appetite enhancement · Spontaneous body sensations · Pain suppression · Muscle relaxation · Tactile euphoria · Headache · Laughter fits · Pupil dilation · Insomnia · Nausea · Restlessness · Trembling · Vomiting
Analysis suppression · Focus suppression · Cognitive fatigue · Confusion · Memory fragmentation · Thought connectivity · Aesthetic enhancement · Immersion enhancement · Novelty enhancement · Thought disorganization · Thought loops · Humor enhancement · Conceptual thinking · Creativity enhancement · Delusions
Confusion · Memory fragmentation · Thought connectivity · Aesthetic enhancement · Immersion enhancement · Novelty enhancement · Thought disorganization · Thought loops · Humor enhancement · Conceptual thinking · Creativity enhancement
Dysphoria · Irritability
Derealization
Timeline
First perceptible effects within seconds to minutes of inhalation — a subtle shift in headspace and mild warmth as CB1 engagement begins.
Rapid intensification of euphoria, body high, and cognitive shift. Effects build noticeably faster than cannabis due to high CB1 affinity.
Maximum intensity — euphoria or dysphoria, sedation, appetite enhancement, cognitive impairment, and time alteration. Adverse effects (tachycardia, anxiety, paranoia) are most likely during this phase.
Gradual return toward baseline. Motor and cognitive impairment may lag behind subjective recovery. The M4 neutral antagonist metabolite may contribute to subjective offset.
Residual sedation, mild appetite effects, and subtle cognitive cloudiness. EEG perturbation documented persisting at 24 hours in mice, suggesting subclinical neural effects beyond subjective recovery.
⚠ Do not drive or operate machinery for at least 4 hours after use — subclinical cognitive impairment may persist beyond subjective recovery.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- THC · JWH-018 · JWH-250
Toxicity
No lethal dose has been established for JWH-073 in any species. This is a critical evidence gap for a compound with documented human exposure.
Acute toxicity
JWH-073's full agonist status means effects can escalate without a ceiling,[2] producing a steeper dose-toxicity curve than cannabis.[22] Case reports document seizures, rapid or dangerously slow heartbeat, heart attacks, acute psychosis, muscle breakdown, kidney injury, and multi-organ failure.[6][23][24] A review of roughly 4,000 synthetic cannabinoid cases found at least 26 deaths across the class.[9]
The acute toxicity of JWH-073 should be considered moderate to high. Case reports document seizures, heart emergencies, psychosis, and multi-organ failure. Most presentations are self-limiting, but severe outcomes occur unpredictably.
Heart and circulation
Rapid heartbeat is the most common adverse effect, appearing in 37–77% of synthetic cannabinoid emergency presentations.[9] Heart rate can shift from dangerously fast to dangerously slow.[23] One case documented a heart attack, bleeding in the brain, and reversible heart muscle damage.[24]
Cell toxicity
JWH-073 damaged cell membranes and caused DNA damage in mouth, breast, and liver cell lines at high concentrations in laboratory tests.[25] These concentrations exceeded expected blood levels, though direct tissue exposure during smoking may approach harmful thresholds.[25]
Psychological risks
JWH-073 carries a higher psychosis risk than cannabis.[22] Three factors converge: full CB1 agonism produces greater receptor activation than cannabis, the higher potency means smaller doses achieve equivalent exposure, and no CBD is present to moderate the effect.[22]
Case reports document acute psychosis with paranoia, delusions, hallucinations, and severe agitation.[6][7] One fatal case involved psychiatric breakdown and self-inflicted lethal injury.[26] Psychotic episodes occur more frequently in inexperienced users and those with pre-existing psychiatric vulnerability.[22]
Tolerance and dependence
Tolerance develops through CB1 receptor desensitization — the receptor becomes less responsive, and fewer copies remain on cell surfaces. Full agonists drive this process faster than partial agonists like Δ9-THC.[27][2] Cross-tolerance exists with all cannabinoids including THC.
Physical and psychological dependence are documented.[8][28] Withdrawal resembles cannabis withdrawal but may be more severe.[9] Benzodiazepines and antipsychotics have been used for symptom relief.[8]
Drug Interactions
JWH-073 and JWH-018 together produce synergistic enhancement of cannabis-like effects at multiple dose ratios[29] — directly relevant to Spice/K2 products, which often contain multiple synthetic cannabinoids in unknown ratios. Sub-threshold doses of JWH-073 combined with JWH-250 synergistically impair motor function and boost dopamine release.[17]
Liver enzyme inhibitors (such as fluconazole or amiodarone) could slow JWH-073's breakdown and increase exposure; enzyme inducers (such as rifampin) could accelerate clearance.inferred No published data exist for interactions with stimulants or psychedelics, though combined dopamine activation from cocaine and JWH-073 would plausibly compound cardiovascular strain.
Contraindications
6 known- History of psychosis or schizophrenia (absolute): full CB1 agonism markedly elevates the risk of triggering acute psychotic episodes.[22] No CBD is present to moderate this risk.
- Heart conditions (absolute): documented rapid and dangerously slow heart rates, heart attacks, and reversible heart muscle damage.[23][24]
- Concurrent stimulant use (relative): combined dopamine and epinephrine activation may compound cardiovascular strain.inferred
- Adolescent or young adult use (relative): younger users are disproportionately represented in severe adverse outcome reports.[7]
- Seizure disorder (relative): JWH-073 lowers the seizure threshold in animal models,[17] and seizures are documented in human cases.[6]
- Pregnancy and breastfeeding (absolute): no reproductive toxicity data exist. Given the high CB1 affinity and full agonist status, exposure during development cannot be considered safe.safety citation needed
Harm Reduction[edit]
Forms & Identification
JWH-073 almost exclusively appears as a component of herbal smoking blends — dried plant material sprayed with a synthetic cannabinoid solution. Labeling is unreliable: identity, concentration, and number of active compounds vary between brands, batches, and even portions of the same packet. Uneven spraying means one pinch may deliver a trivial dose while the next delivers a dangerous one.
Reagent testing can confirm the presence of a synthetic cannabinoid but cannot identify the specific compound or quantify the dose in a given sample.
Guidelines
- Test any product with available reagent kits before use. A positive result confirms a synthetic cannabinoid class but not identity or dose.
- Start with the smallest possible amount — a single shallow inhalation — and wait at least 15–20 minutes before considering more. The distance between a comfortable experience and an emergency is very short.
- Use only in the presence of a sober companion who knows what was consumed and can call for help.
- Avoid redosing within the same session. Acute effects from the previous dose may not have fully manifested.
- Eat a light meal beforehand and stay hydrated. Avoid alcohol, which compounds sedation and impairs judgment.
- Do not drive or operate machinery. Cognitive and motor impairment outlasts subjective effects.
Set & Setting
The steep dose curve and unpredictable product composition make set and setting unusually important with JWH-073. A calm, familiar environment with a sober companion present is strongly recommended. Anyone with a history of anxiety, panic attacks, or psychotic episodes faces substantially elevated risk and should consider abstinence.
Aftercare & integration. After acute effects resolve, residual cognitive dulling and low mood may persist for several hours to a day. Prioritize sleep, light nutrition, and gentle activity. Avoid any cannabinoid — synthetic or natural — for at least several days to allow CB1 recovery.
If the experience involved significant anxiety, paranoia, or psychotic symptoms, discuss it with a trusted person or a mental health professional. Recurring intrusive thoughts, persistent anxiety, or lingering perceptual disturbances after use warrant professional evaluation.
Recovery & Support
Daily synthetic cannabinoid use can produce physical and psychological dependence. Withdrawal may include irritability, insomnia, reduced appetite, anxiety, and cravings — resembling cannabis withdrawal but potentially more intense.[9] Medical supervision is advisable for anyone with a sustained daily habit, as some cases have required benzodiazepine or antipsychotic support.[8]
Peer support groups, addiction counselors, and substance use helplines can provide ongoing guidance. Substituting natural cannabis for synthetic cannabinoids during tapering has been reported by some users,[28] though this should be discussed with a healthcare provider rather than managed independently.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety or mild nausea is common and typically self-limiting. Seek immediate help if any of the following occur: seizures or uncontrollable muscle jerking, chest pain or irregular heartbeat, loss of consciousness or unresponsiveness, severe confusion with inability to recognize surroundings, self-harming behavior or expressed intent to self-harm, vomiting that does not stop.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not restrain a seizing person — move objects away to prevent injury and let the seizure run its course.
- 4. Keep the person calm and in a quiet environment. Reduce stimulation.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance ("synthetic cannabinoid" or the product name), the amount if known, the time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
No reversal agent exists for synthetic cannabinoid toxicity. Treatment is supportive.
Legal Status[edit]
JWH-073 is a controlled substance in all major Western jurisdictions, prohibited as part of the regulatory response to synthetic cannabinoids appearing in "Spice" and "K2" products beginning in 2008–2009.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily placed March 1, 2011 as "imminent hazard to public safety";[14] permanently scheduled March 2012[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Banned under generic 3-(1-naphthoyl)indole definition, approximately December 2009[13] |
| Australia | Schedule 9 — Prohibited substance (Poisons Standard) | Effective July 8, 2011[13] |
| Canada | Controlled substance (Controlled Drugs and Substances Act) | Listed explicitly by compound name[13] |
| European Union | Varies by member state | No EU-wide Council Decision identified for JWH-073 specifically. Monitored by EMCDDA; reported by Austria July 2010. Individual member states addressed scheduling under national legislation. |
Analog act considerations
In jurisdictions with structural analog legislation — such as the US Federal Analogue Act — structural analogs of JWH-073 may be treated as controlled substances when intended for human consumption. Permanent scheduling of JWH-073 makes this mostly irrelevant for this compound, but it applies to novel naphthoylindole derivatives not yet individually scheduled.
Legal status varies by jurisdiction and changes frequently. This information is not legal advice.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- THC · JWH-018 · JWH-250
Toxicity
No lethal dose, therapeutic index, or dose-response lethality data have been published for JWH-073 in any species. The absence of these fundamental parameters is a critical evidence gap for a compound with documented human exposure.
Acute toxicity
JWH-073's full agonist status at CB1[2] is the central safety distinction from cannabis. Full agonism means effects can escalate without the ceiling that partial agonists like Δ9-THC impose, producing a steeper dose-toxicity curve.[22] Case reports document severe outcomes including generalized seizures, rapid heart rate shifting to dangerously slow heart rate, heart attacks, acute psychosis with self-harm, muscle breakdown, kidney injury, and multi-organ failure.[6][23][24]
A systematic review of roughly 4,000 synthetic cannabinoid cases identified at least 26 deaths across the broader class, though JWH-073-specific mortality cannot be isolated from aggregate data.[9] In mice, doses exceeding 1 mg/kg produced seizures, involuntary muscle jerking, exaggerated reflexes, and aggression — all blocked by the CB1 antagonist AM251.[17]
The acute toxicity of JWH-073 should be considered moderate to high. Case reports document seizures, heart emergencies, psychosis, and multi-organ failure. Most presentations are self-limiting, but severe outcomes occur unpredictably.
Heart and circulation
Rapid heart rate is the most commonly reported adverse effect, appearing in 37–77% of synthetic cannabinoid emergency presentations.[9] The first laboratory-confirmed cardiac case involved a 17-year-old with chest pain and a heart rate that shifted from dangerously fast to dangerously slow.[23] A separate case documented a heart attack, bleeding in the brain, and reversible heart muscle damage.[24]
Cell toxicity
Laboratory studies found that JWH-073 damaged cell membranes in mouth and breast tissue cell lines at high concentrations, and caused DNA damage in mouth cells and liver cells.[25] The researchers noted that these toxic concentrations exceeded expected blood levels, though direct tissue exposure during smoking may approach harmful thresholds.[25]
Psychological risks
Synthetic cannabinoids including JWH-073 carry psychosis risk exceeding that of cannabis.[22] Three factors converge: full CB1 agonism produces greater receptor activation than cannabis, higher potency means lower doses achieve equivalent receptor occupancy, and the absence of CBD removes a component that may moderate psychosis risk in natural cannabis.[22]
Case reports confirm acute psychosis with paranoia, delusions, hallucinations, and severe agitation.[6][7] One fatal case involved extreme psychiatric breakdown resulting in self-inflicted lethal injury.[26] Anxiety, paranoia, and confusion appear dose-dependent, though no controlled data allow incidence to be quantified at specific dose levels.
Psychosis-like episodes occur more frequently with synthetic cannabinoids than with natural cannabis, particularly in inexperienced users and those with pre-existing psychiatric vulnerability.[22]
Tolerance and dependence
Tolerance to JWH-073 develops through CB1 receptor desensitization and downregulation — the receptor becomes less responsive and fewer copies remain on cell surfaces. As a full agonist,[2] JWH-073 is expected to drive tolerance more rapidly than partial agonists like Δ9-THC, because full activation triggers stronger receptor shutdown mechanisms.[27] Cross-tolerance exists with all other cannabinoids, including THC.
Physical and psychological dependence on JWH-073 and related synthetic cannabinoids is documented.[8][28] Daily use leads to dependence; withdrawal symptoms resemble cannabis withdrawal but may be more severe.[9] Some symptom relief has been reported with benzodiazepines (for agitation) and quetiapine (for psychosis).[8] Users sometimes substitute synthetic cannabinoids to manage cannabis withdrawal.[28]
Drug Interactions
The best-documented interactions involve combinations of synthetic cannabinoids with each other. JWH-018 and JWH-073 together produce synergistic enhancement of cannabis-like effects and pain suppression at multiple dose ratios, with laboratory evidence suggesting multiple CB1 binding sites.[29] Sub-threshold doses of JWH-073 combined with JWH-250 synergistically impair motor function and enhance dopamine release in the mesolimbic pathway.[17] These findings are directly relevant to Spice/K2 products, which frequently contain multiple synthetic cannabinoids in unknown ratios.
Inhibitors of the liver enzyme that metabolizes JWH-073 (such as fluconazole or amiodarone) could theoretically slow breakdown and increase exposure to the active compound; enzyme inducers (such as rifampin) could accelerate clearance.inferred
No published data exist for interactions with stimulants, psychedelics, or other drug classes. Both cocaine and synthetic cannabinoids promote dopamine release; additive cardiovascular stress is pharmacologically plausible but unstudied.
Contraindications
6 known- History of psychosis or schizophrenia (absolute): full CB1 agonism at high potency carries markedly elevated risk of triggering acute psychotic episodes.[22] The absence of CBD in synthetic cannabinoid products removes a potential moderating factor.
- Heart conditions (absolute): documented cases of rapid and dangerously slow heart rates, heart attacks, and reversible heart muscle damage[23][24] rule out use by anyone with pre-existing cardiovascular disease.
- Concurrent stimulant use (relative): combined dopamine and epinephrine activation may compound cardiovascular strain.inferred
- Adolescent or young adult use (relative): younger users are disproportionately represented in severe adverse outcome presentations.[7]
- Seizure disorder (relative): JWH-073 lowers the seizure threshold in animal models,[17] and seizures are documented in human case reports.[6]
- Pregnancy and breastfeeding (absolute): no reproductive toxicity data exist. Given the compound's high CB1 affinity and full agonist status, exposure during development cannot be considered safe.safety citation needed
Harm Reduction[edit]
Forms & Identification
JWH-073 almost exclusively appears as a component of herbal smoking blends — dried plant material sprayed with a solution of the synthetic compound. The core challenge is that these products carry no reliable labeling: the identity, concentration, and number of active compounds vary between brands, batches, and even different portions of the same packet. Uneven spraying means one pinch may contain a trivial dose while the next delivers a dangerous one. Reagent testing can confirm the presence of a synthetic cannabinoid but cannot quantify the dose in a given sample.
Guidelines
- Test any product with available reagent kits before use, understanding that a positive result confirms a synthetic cannabinoid class but not identity or dose.
- Start with the smallest possible amount — a single shallow inhalation — and wait at least 15–20 minutes before considering more. The steep dose-response means the distance between a comfortable experience and an emergency is very short.
- Use only in the presence of a sober sitter who knows what was consumed and can call for help.
- Avoid redosing within the same session. Tolerance develops rapidly, but acute effects from the previous dose may not have fully manifested.
- Eat a light meal beforehand and stay hydrated, but avoid alcohol, which compounds sedation and impairs judgment.
- Do not drive or operate machinery. Cognitive and motor impairment outlasts subjective effects.
Set & Setting
The steep dose-response curve and unpredictable product composition make set and setting unusually important with JWH-073. A calm, familiar environment with a sober companion present is strongly recommended. Users with any history of anxiety, panic attacks, or psychotic episodes face substantially elevated risk and should consider abstinence.
Aftercare & integration. After the acute effects resolve, residual cognitive dulling and low mood may persist for several hours to a day. Prioritize sleep, light nutrition, and gentle activity. Avoid using any cannabinoid — synthetic or natural — for at least several days to allow CB1 recovery.
If the experience involved significant anxiety, paranoia, or psychotic symptoms, discuss it with a trusted person or a mental health professional. Recurring intrusive thoughts, persistent anxiety, or lingering perceptual disturbances after use warrant professional evaluation.
Recovery & Support
Daily synthetic cannabinoid use can produce physical and psychological dependence. Withdrawal symptoms may include irritability, insomnia, reduced appetite, anxiety, and cravings — resembling cannabis withdrawal but potentially more intense.[9] Medical supervision is advisable for individuals with a sustained daily habit, as some cases have required short-term benzodiazepine or antipsychotic support.[8]
Peer support groups, addiction counselors, and substance use helplines can provide ongoing guidance. Substituting natural cannabis for synthetic cannabinoids during tapering has been reported by some users,[28] though this should be discussed with a healthcare provider rather than managed independently.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety or mild nausea during the experience is common and typically self-limiting. Seek immediate help if any of the following occur: seizures or uncontrollable muscle jerking, chest pain or irregular heartbeat, loss of consciousness or unresponsiveness, severe confusion with inability to recognize surroundings, self-harming behavior or expressed intent to self-harm, vomiting that does not stop.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not restrain a seizing person — move objects away to prevent injury and let the seizure run its course.
- 4. Keep the person calm and in a quiet environment. Reduce stimulation.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance ("synthetic cannabinoid" or the product name), the amount if known, the time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
No reversal agent exists for synthetic cannabinoid toxicity. Treatment is supportive.
Legal Status[edit]
JWH-073 is a controlled substance in all major Western jurisdictions. Its prohibition followed the broader regulatory response to synthetic cannabinoids that appeared in "Spice" and "K2" herbal smoking blends beginning in 2008–2009. Most jurisdictions used either compound-specific scheduling or generic structural definitions covering the naphthoylindole class.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily placed March 1, 2011 as "imminent hazard to public safety";[14] permanently scheduled March 2012[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Banned under generic 3-(1-naphthoyl)indole definition, approximately December 2009[13] |
| Australia | Schedule 9 — Prohibited substance (Poisons Standard) | Effective July 8, 2011[13] |
| Canada | Controlled substance (Controlled Drugs and Substances Act) | Listed explicitly by compound name[13] |
| European Union | Varies by member state | No EU-wide Council Decision identified for JWH-073 specifically. Monitored by EMCDDA; reported by Austria July 2010. Individual member states addressed scheduling under national legislation. |
Analog act considerations
In jurisdictions with structural analog legislation (such as the US Federal Analogue Act), structural analogs of JWH-073 that are "substantially similar" in chemical structure or pharmacological effect may be treated as controlled substances when intended for human consumption. The permanent scheduling of JWH-073 itself makes the analog act unnecessary for this specific compound, but it remains relevant for novel naphthoylindole derivatives that have not been individually scheduled.
Frequently asked questions
What is JWH-073?
JWH-073 is a synthetic cannabinoid of the naphthoylindole class, acting as a full agonist at CB1 and CB2 receptors. First synthesized at Clemson University as a research tool, it entered recreational markets in 2009 and is Schedule I in the United States.
How long does JWH-073 last?
Total duration by route of administration — Smoked: 1 – 2 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for JWH-073?
Psychedex publishes a dosage table for JWH-073 on this page covering these routes of administration: smoked. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with JWH-073?
The highest-severity documented interactions for JWH-073: GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous), Ketamine, DXM, PCP (Dangerous), Local anesthetics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is JWH-073 addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for JWH-073: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with THC, JWH-018, JWH-250, cannabinoids (all CB1 agonists). See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdefghBrents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity — Biochemical Pharmacology doi:10.1016/j.bcp.2012.01.004
- [3]
- [4] ^abDresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds — Journal of Mass Spectrometry doi:10.1002/jms.1811
- [5]
- [6] ^abcdSimmons J, Cookman L, Kang C, Skinner C (2011) Three cases of spice exposure — Clinical Toxicology doi:10.3109/15563650.2011.584316
references
- [1]
- [2] ^abcdefghiBrents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity — Biochemical Pharmacology doi:10.1016/j.bcp.2012.01.004
- [3]
- [4] ^abDresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds — Journal of Mass Spectrometry doi:10.1002/jms.1811
- [5]
- [6] ^abcdSimmons J, Cookman L, Kang C, Skinner C (2011) Three cases of spice exposure — Clinical Toxicology doi:10.3109/15563650.2011.584316